A Phase II and Biomarker Study of Cabozantinib in Patients with Advanced Cholangiocarcinoma

BACKGROUND: Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond the first-line gemcitabine/platinum-based chemotherapy. We performed a single arm phase II and biomarker study of cabozantinib, a multikinase inhibitor with potent activity against VEGFR2 and ME...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer
Päätekijät: Goyal, Lipika, Zheng, Hui, Yurgelun, Matthew B., Abrams, Thomas A., Allen, Jill N., Cleary, James M., Knowles, Michelle, Regan, Eileen, Reardon, Amanda, Khachatryan, Anna, Jain, Rakesh K., Nardi, Valentina, Borger, Darrell R., Duda, Dan G., Zhu, Andrew X.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5444988/
https://ncbi.nlm.nih.gov/pubmed/28192597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30571
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia